Evidence map›Paper›PMID 39972326›Full record

ArticleAIDS research and therapy2025

Experiences, challenges, gaps, and strategies for counselling persons presenting with advanced HIV-associated meningitis in Uganda.

Alisat Sadiq, Richard Kwizera, Tadeo K Kiiza, Peruth Ayebare, Cynthia Ahimbisibwe, Jane Frances Ndyetukira, David R Boulware, David B Meya

3 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01075152 phase4completednot on this map

Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis

TypeinterventionalSponsorUniversity of MinnesotaRan2010 to 2013Enrolled177ConditionsCryptococcal Meningitis, HIV Infections, AIDSArmsefavirenz, nucleoside
NCT01802385 phase3completednot on this map

Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis

TypeinterventionalSponsorUniversity of MinnesotaRan2015 to 2017Enrolled460ConditionsCryptococcal Meningitis, Fungal MeningitisArmsSertraline
NCT04031833 phase1 / phase2completednot on this map

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial

TypeinterventionalSponsorMatinas BioPharma Nanotechnologies, Inc.Ran2019 to 2023Enrolled178ConditionsCryptococcal MeningitisArmsMAT2203, Amphotericin B
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alisat SadiqInfectious Diseases Institute, College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda.
Richard KwizeraInfectious Diseases Institute, College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda. kwizerarichard@ymail.com.
Tadeo K KiizaInfectious Diseases Institute, College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda.
Peruth AyebareInfectious Diseases Institute, College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda.
Cynthia AhimbisibweInfectious Diseases Institute, College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda.
Jane Frances NdyetukiraInfectious Diseases Institute, College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda.
David R BoulwareDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
David B MeyaInfectious Diseases Institute, College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvanced HIV disease (AHD) is still a significant problem in Uganda despite the test-and-treat strategy and the increased access to antiretroviral therapy (ART). Meningitis remains a major cause of morbidity and mortality in people with AHD. HIV counselling is essential and plays an important role in managing persons with AHD-related meningitis. We sought to describe the experiences and challenges we faced during counselling of these individuals, highlighting the strategies, gaps and how we can fill them.

methodsFirst, we describe our experience and major challenges in counselling people with AHD-related meningitis. Second, we describe the strategies we used to overcome each of these challenges. Third, we highlight the health system gaps and recommend solutions.

resultsMajor challenges include the presence of altered mental status, unknown HIV status at admission, non-disclosure of HIV status to family, insufficient ART history, caretakers-related challenges, pill burden, multiple drug side effects, invasive clinical procedures, myths about medical procedures, poverty, lack of privacy during counselling in the wards, patients/caretakers seeking alternative non-medical interventions including religious, traditional, and herbal therapies before and after initiating meningitis treatment.

conclusionsPersons with AHD-related meningitis need daily and special consideration during counselling as part of the package of care to improve treatment outcomes. TRIAL REGISTRATIONS: NCT01075152 (23 Feb 2010), NCT01802385 (28 Feb 2013), ISRCTN42218549 (24 April 2018), ISRCTN72509687 (13 July 2017), NCT04031833 (01 January 2019), ISRCTN15668391 (23 May 2019), ISRCTN18437550 (05/11/2021).

Indexed as

CounselingHIV InfectionsMeningitisAdultAnti-HIV AgentsFemaleHumansMaleUgandaAnti-HIV AgentsAdvanced HIV DiseaseCounsellingHIVMeningitisUganda

Identifiers

PMID39972326
PMCPMC11841227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.